After consulting with outside advisers, the Texas Health and Human Services Commission mulls changing its recommendation to Medicaid that Gilead Sciences' (GILD +3.9%) Sovaldi be restricted to the sickest hepatitis C patients due to its high cost. The plan's July start is now on hold while the agency examines its options.
Also on hold is the state's plan to make supplemental payments to insurers to partially offset the drug's cost.
Insurers in California and Florida have also asked their states to pay them directly so they can avoid losing money in their contracts. California is still evaluating the issue while Florida has no plans to carve out the drug.